Nyrada Quarterly Activities Report & Appendix 4C
Nyrada remains on track for 2QFY2025 commencement of first in-human Phase I clinical trial for its Brain Injury drug candidate… Read more
Nyrada Signs Strategic Partnership with US Brain Injury Detection and Monitoring Company
Highlights: •Nyrada signs strategic partnership agreement with Rebion to advance brain injury therapies and outcomes. •Partnership will facilitate joint research… Read more
Nyrada Inc – Nyrada Commences Walter Reed Traumatic Brain Injury Study
Highlights: •Walter Reed Army Institute of Research study of NYR-BI03 in traumatic brain injury has commenced and is expected to… Read more
Nyrada Inc – Investor Presentation
April 2024 Investor Presentation
Nyrada Inc – Nyrada Quarterly Activities Report & Appendix 4C
Highlights: • Lead Brain Injury Program drug candidate NYR-BI03 demonstrated strong efficacy: – rescued average 42% of the brain injury… Read more
Nyrada Inc – Nyrada Commences Key Brain Injury Program Preclinical Study
Highlights: •NYR-BI03 Good Laboratory Practice (GLP) safety testing studies have commenced and are expected to conclude in 2HCY2024. •First in-human… Read more
Nyrada Inc -Nyrada Successfully Raises $1.755 Million via Placement
Highlights: •Nyrada has successfully raised $1.755 million of new equity capital (before costs). •Nyrada Directors will subscribe for an additional… Read more
Nyrada Inc (ASX:NYR) Statistically Significant Neuroprotection Achieved in Nyrada’s Preclinical Brain Injury Study
Nyrada Inc. (ASX: NYR) have released results from an animal study of their lead Brain Injury program drug candidate NYR-BI03…. Read more
Nyrada Inc -Statistically Significant Neuroprotection Achieved in Nyrada’s Preclinical Brain Injury Study
Highlights: •Nyrada’s lead Brain Injury Program drug candidate NYR-BI03 demonstrated strong efficacy in reducing injury in a preclinical study. •NYR-BI03… Read more
